This inventor holds 2 USPTO granted patents. Top assignees: Mitsui Toatsu Chemicals, Incorporated, Schering Aktiengesellschaft. Active years: 1996-2002.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Chiba-ken, JP (1996)
- Chiba, JP (2002)
Company Filing History:
1 out of 1,379 
1 out of 1,409 Years Active: 1996-2002
Title: Takeshi Kamioka: Pharmaceutical Inventions and Patent Contributions.
Introduction.
Takeshi Kamioka is an inventor associated with pharmaceutical inventions and patent activity in Chiba, Japan. His listed work includes patents concerning human growth hormone therapy and pyrrolidinone derivatives. He is credited with 2 patents.
Latest Patents.
“Therapeutic Use of 20-Kilodalton Human Growth Hormone” describes administering authentic human growth hormone with a molecular weight of 20,000 daltons to adults. The patent identifies potential uses including improving body composition, stimulating lipolysis, increasing serum insulin-like growth factor I, and providing replacement therapy for people with growth hormone deficiency.
“Pyrrolidinone Derivatives” concerns compounds, or their salts, proposed as active ingredients in antipsychotic and ischemic cerebral disease treatments. The patent states that these drugs do not induce extrapyramidal side effects.
Career Highlights.
Kamioka’s listed company affiliations include Schering Aktiengesellschaft and Mitsui Toatsu Chemicals, Incorporated. His patent portfolio reflects work in pharmaceutical research and therapeutic applications.
Collaborations.
His listed coworkers include Kazutoshi Horikomi and Miwa Ikeda.
Conclusion.
Takeshi Kamioka’s recorded inventions address potential treatments involving human growth hormone and pyrrolidinone derivatives, reflecting his contributions to pharmaceutical innovation.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile